PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.
about
PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
PE859, a novel tau aggregation ...... of neural dysfunction in vivo.
@ast
PE859, a novel tau aggregation ...... of neural dysfunction in vivo.
@en
type
label
PE859, a novel tau aggregation ...... of neural dysfunction in vivo.
@ast
PE859, a novel tau aggregation ...... of neural dysfunction in vivo.
@en
prefLabel
PE859, a novel tau aggregation ...... of neural dysfunction in vivo.
@ast
PE859, a novel tau aggregation ...... of neural dysfunction in vivo.
@en
P2093
P2860
P1433
P1476
PE859, a novel tau aggregation ...... of neural dysfunction in vivo.
@en
P2093
Hachiro Sugimoto
Ichiro Hijikuro
Makoto Ogo
Michiaki Okuda
Naoki Tanaka
Nobuhiko Tsuchiya
Shigeru Akasofu
Shinichi Nakayama
Takashi Takahashi
Xiaofeng Wu
P2860
P304
P356
10.1371/JOURNAL.PONE.0117511
P407
P577
2015-02-06T00:00:00Z